Innovent Biologics, Inc. (IVBXF)
- Previous Close
4.8900 - Open
5.0000 - Bid --
- Ask --
- Day's Range
5.0000 - 5.0000 - 52 Week Range
3.5500 - 6.4100 - Volume
200 - Avg. Volume
3,322 - Market Cap (intraday)
8.054B - Beta (5Y Monthly) 0.17
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0900 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People's Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People's Republic of China.
www.innoventbio.comRecent News: IVBXF
Performance Overview: IVBXF
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IVBXF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IVBXF
Valuation Measures
Market Cap
8.05B
Enterprise Value
7.04B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
9.11
Price/Book (mrq)
4.66
Enterprise Value/Revenue
1.13
Enterprise Value/EBITDA
-6.73
Financial Highlights
Profitability and Income Statement
Profit Margin
-16.56%
Return on Assets (ttm)
-5.49%
Return on Equity (ttm)
-8.84%
Revenue (ttm)
6.21B
Net Income Avi to Common (ttm)
-1.03B
Diluted EPS (ttm)
-0.0900
Balance Sheet and Cash Flow
Total Cash (mrq)
10.97B
Total Debt/Equity (mrq)
28.90%
Levered Free Cash Flow (ttm)
--
Company Insights: IVBXF
IVBXF does not have Company Insights